New hope for Hard-to-Treat ovarian cancer: drug combo shows promise in early trial
NCT ID NCT05483933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also looked for signs that the tumors shrank. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Center
Vancouver, British Columbia, BC V5Z 4E6, Canada
-
City of Hope
Duarte, California, 91010, United States
-
Guy's & St Thomas' NHS Foundation Trust
London, SE1 7EH, United Kingdom
-
Hospital Clinic de Barcelona Servicio de Oncología, Esc. 2, Planta 5 dcha
Barcelona, Catalonia, 08036, Spain
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Hospital Universitari Vall D Hebron
Madrid, 28013, Spain
-
Hospital Universitario Dr. Josep Trueta - ICO de Girona, Servicio de Oncología Av. Francia s/n
Girona, 17007, Spain
-
Hospital Universitario Fundacion Jimenez Diaz START Madrid-FJD- Unidad de Ensayos Fase I
Madrid, 28040, Spain
-
Hospital Universitario Quirón-Dexeus Servicio de Oncologia Médica
Barcelona, 08028, Spain
-
Hospital Universitario Virgen de la Arrixaca. Servicio de Oncología Ctra. Madrid-Cartagena, s/n
Murcia, 30120, Spain
-
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, Lancashire, PR2 9HT, United Kingdom
-
McGill University Health Care
Montreal, Quebec, H4A 3J1, Canada
-
Robert H.Lurie ComprehensiveCancer Center, Northwestern University
Chicago, Illinois, 60611, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Stephenson Cancer Center, OU Health/ Sarah Cannon Research Institute
Oklahoma City, Oklahoma, 73104, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom
-
University health Network (UHN)-University of Toronto
Toronto, Ontario, M5G 2M9, Canada
-
University of Arkansas for Medical sciences
Little Rock, Arkansas, 72205, United States